AIM ImmunoTech (STU:HXB2) Days Sales Outstanding : 68.44 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Days Sales Outstanding?

AIM ImmunoTech's average Accounts Receivable for the three months ended in Dec. 2023 was €0.05 Mil. AIM ImmunoTech's Revenue for the three months ended in Dec. 2023 was €0.06 Mil. Hence, AIM ImmunoTech's Days Sales Outstanding for the three months ended in Dec. 2023 was 68.44.

The historical rank and industry rank for AIM ImmunoTech's Days Sales Outstanding or its related term are showing as below:

STU:HXB2' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.05 Med: 363.7 Max: 4293.28
Current: 1590.1

During the past 13 years, AIM ImmunoTech's highest Days Sales Outstanding was 4293.28. The lowest was 20.05. And the median was 363.70.

STU:HXB2's Days Sales Outstanding is ranked worse than
97.09% of 894 companies
in the Biotechnology industry
Industry Median: 72.38 vs STU:HXB2: 1590.10

AIM ImmunoTech's Days Sales Outstanding declined from Dec. 2022 (2,723.73) to Dec. 2023 (68.44).

AIM ImmunoTech Days Sales Outstanding Historical Data

The historical data trend for AIM ImmunoTech's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Days Sales Outstanding Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

357.76

92.61

2,269.75

4,163.20

3,121.24

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															2,723.73	3,202.68	1,961.88	79.58	68.44

Competitive Comparison of AIM ImmunoTech's Days Sales Outstanding

For the Biotechnology subindustry, AIM ImmunoTech's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Days Sales Outstanding falls into.

AIM ImmunoTech Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

AIM ImmunoTech's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1.582	+	0)	/	1 )	/	0.185	*	365
=	1.582					/	0.185	*	365
=	3,121.24

AIM ImmunoTech's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.045	+	0)	/	1 )	/	0.06	*	365 / 4
=	0.045					/	0.06	*	365 / 4
=	68.44

AIM ImmunoTech (STU:HXB2) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

AIM ImmunoTech Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines